Clinical significance of serum transforming growth factor-β1 in lung cancer
| Autor: | Yu-Lei Hou, Yong-Chang Wu, Cheng-Hua Li, Cheng-Jun Xue, Yan-Feng Wu, Zi-He Dong, Hui Chen, Hai-Xia Luo |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Pathology Lung Neoplasms Epidemiology Enolase Enzyme-Linked Immunosorbent Assay Gastroenterology Transforming Growth Factor beta1 Cytokeratin Internal medicine medicine Biomarkers Tumor Humans Clinical significance Lung cancer Aged Neoplasm Staging business.industry Middle Aged medicine.disease Oncology ROC Curve Clinical diagnosis Case-Control Studies Female business Human cancer Transforming growth factor |
| Zdroj: | Cancer epidemiology. 37(5) |
| ISSN: | 1877-783X |
| Popis: | Background : Transforming growth factor-β1 (TGF-β1) plays a critical role in human cancer development. Present study aimed to explore the clinical significance of serum TGF-β1 levels in patients with lung cancer and analyze the relationship between TGF-β1 and existing tumor markers for lung cancer. Methods : Serum was collected from 118 patients with lung cancer and 40 healthy volunteers. Serum TGF-β1 levels were measured by enzyme-linked immunosorbent assay (ELISA), and the association with various clinical characteristics was analyzed. The diagnostic value of TGF-β1 was assessed alone and in combination with existing tumor markers for lung cancer. Results : Serum TGF-β1 levels were significantly higher in patients with lung cancer compared to healthy volunteers [0.6×10 5 (0.4×10 5 , 0.9×10 5 )pg/ml vs 0.5×10 5 (0.3×10 5 , 0.7×10 5 )pg/ml, P =0.040]. Although there was a positive correlation between serum TGF-β1 levels and advanced stages, the significant difference was not found between early stages and advanced stages ( P =0.116). The ability of serum TGF-β1 to discriminate lung cancer at a cutoff value of 79,168pg/ml exhibited sensitivity of 30.6% and specificity of 97.5%. Serum TGF-β1 levels were correlated to cytokeratin fragment 21-1 (CYFRA21-1; R =0.308, P =0.020) and neuron-specific enolase (NSE; R =0.558, P =0.003). The diagnostic accuracy rates for the existing lung-tumor markers, as SCC, CYFRA21-1, and NSE, were increased from 20.0%, 34.6%, and 45.9% to 48.9%, 51.7%, and 54.5%, respectively by the inclusion of serum TGF-β1 levels. Conclusion : Quantification of serum TGF-β1 levels by ELISA may provide a novel complementary tool for the clinical diagnosis of lung cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect